# RETINAL (retinal) — Global Cosmetic Regulatory & Formulation Monograph

- **Canonical URL**: https://www.inciname.com/en/ingredients/retinal
- **Standard INCI**: `RETINAL`
- **KR MFDS Standard Name**: `레틴알`
- **CAS No.**: `116-31-4`
- **EC / EINECS No.**: `204-135-8`
- **Origin**: `vitamin`
- **Functions**: 피부컨디셔닝제
- **Molecular Formula / MW**: `—` (— g/mol)

## 1. 7-Track Official Regulatory Label Names
| Track | Official Label Nomenclature |
| :--- | :--- |
| KR (MFDS Standard) | 레틴알 |
| KR (Former Names) | 레티날 |
| EU (CosIng 1223/2009) | RETINAL |
| US (PCPC / MoCRA INCI) | RETINAL |
| US (FDA OTC Monograph) | — |
| CN (NMPA IECIC) | 视黄醛 |
| JP (JCIA / MHLW QD) | RETINAL  |

## 2. Layer 1 — Global 6-Region Statutory Summary
- **KR (MFDS)**: `none`
- **EU (1223/2009)**: `none`
- **US (FDA/MoCRA)**: `none`
- **CN (NMPA IECIC)**: `allowed` (Entry: `6169`)
- **JP (MHLW)**: `none`
- **ASEAN (ACD)**: `none`



## 3. Layer 2 — Toxicological & Historical Safe Use Concentrations
- Listed within general cosmetic GMP safety thresholds.

## 4. Layer 3 — Formulation Quartiles & Compatibility
- **Optimal pH Window**: 4.5 – 7.5
- **Max Process Temp**: ≤ 70°C
- **Synergy Pairings**: —
- **Incompatibilities**: —

## 5. Academic Monograph
■ [1. Chemical Identity & International Labeling Nomenclature]
  - INCI Name: RETINAL | CAS No.: 116-31-4 | EC No.: 204-135-8
  - Origin: VITAMIN | Functions: Skin Conditioning
  - Physicochemical Profile: Formula      | MW /(Polymer/Complex) | /   | Ionic Nature: non-ionic | CosIng/MFDS 
  - Official Regional Label Names: US [RETINAL] · EU [RETINAL] · CN [视黄醛] · JP [-] · JP Quasi-Drug [-]
■ [2. Dermatological Mechanism of Action & Functional Role]
  - Direct metabolic intermediate between Retinol and Retinoic Acid requiring only a single enzymatic oxidation step. Delivers rapid RAR/RXR-mediated dermal collagen synthesis and epidermal renewal alongside intrinsic antibacterial activity against Cutibacterium acnes.
■ [3. Global 6-Jurisdiction Regulatory Status & Safety Limits (Layer 1 & Layer 2)]
  - Regional Summary: KR: NONE | EU: NONE | US: NONE | CN: ALLOWED | JP: NONE | ASEAN: NONE (CN IECIC (2025) Entry No. 6169 (视黄醛))
  - No specific Annex prohibition or numeric restriction across the 6 major jurisdictions (Permitted under general GMP safety assessment).
  - Official Safety & Historical Use Concentration (Layer 2): Quantum satis (QS) within standard cosmetic safety margins
■ [4. Formulation Dosage Guide by Product Category (Layer 3-A)]
  - Dosage engineered according to primary function  and phase solubility.
■ [5. Formulation Engineering, Stability & Incompatibility Matrix (Layer 3-B)]
  - Addition Phase: Standard Phase 
  - Optimal pH Range: pH 4.5 ~ 7.5  | Max Process Temp:     | Electrolyte Tolerance: MEDIUM
  - Incompatibility / Caution: Perform preliminary compatibility testing when combining with strong electrolytes or extreme pH actives
  - Synergy Pairings: GLYCERIN, PANTHENOL, TOCOPHEROL | Reference Trade Names: RETINAL
■ [6. Peer-Reviewed Literature & Official Compendia Evidence]
  - PMID 28028001 (2017, Prog Retin Eye Res): Pharmacokinetic aspects of retinal drug delivery
  - PMID 30578521 (2018, Adv Exp Med Biol): Drug-Induced Retinal Toxicity
  - PMID 38942228 (2024, Am J Ophthalmol): A Comprehensive Meta-Analysis on the Role of Analgesics and Anti-Inflammatories in Pan-Retinal Photocoagulation

## 6. Linked PubMed Literature
- [PMID: 28028001] Pharmacokinetic aspects of retinal drug delivery — *Prog Retin Eye Res* (2017)
- [PMID: 30578521] Drug-Induced Retinal Toxicity — *Adv Exp Med Biol* (2018)
- [PMID: 38942228] A Comprehensive Meta-Analysis on the Role of Analgesics and Anti-Inflammatories in Pan-Retinal Photocoagulation — *Am J Ophthalmol* (2024)
- [PMID: 40319468] Beyond the injection: delivery systems reshaping retinal disease management — *Expert Opin Pharmacother* (2025)
- [PMID: 30578525] Genetic Testing for Inherited Retinal Dystrophy: Basic Understanding — *Adv Exp Med Biol* (2018)
- [PMID: 12434490] Novel approaches for retinal drug delivery — *Ophthalmol Clin North Am* (2002)
- [PMID: 42320944] Presumed enterovirus-associated bilateral asymmetrical retinitis with haemorrhagic occlusive retinal vasculitis secondary to hand, foot and mouth disease — *BMJ Case Rep* (2026)
- [PMID: 42317941] Bilateral Acute Retinal Pigment Epitheliitis Diagnosed and Monitored Using Multimodal Imaging: A Case Report — *Cureus* (2026)
- [PMID: 42311744] From Field to Fundus: A Peripheral Retinal Tear Following Football-Related Ocular Trauma — *Cureus* (2026)
- [PMID: 42285040] Diabetic retinal disease: Five trials to watch — *Med* (2026)
- [PMID: 42260560] Spontaneous closure of secondary full-thickness macular hole following pars plana vitrectomy for rhegmatogenous retinal detachment: a case report and literature review — *J Med Case Rep* (2026)
- [PMID: 42313163] Enhanced S-cone syndrome in a family: first long-term (12-year) follow-up and literature review — *Graefes Arch Clin Exp Ophthalmol* (2026)
- [PMID: 42305768] A Case Report of Presumed West Nile Virus Chorioretinitis in a Non-Endemic Area: Atypical Serology and Imaging Features of Old and New Lesions — *Case Rep Ophthalmol* (2026)
- [PMID: 42284254] Prognostic factors associated with visual field recovery in non-arteritic anterior ischemic optic neuropathy — *PLoS One* (2026)
- [PMID: 42278081] Glaucoma in a Siberian Tiger (Panthera tigris altaica) Maintained Under Human Care: A Case Report — *Animals (Basel)* (2026)
- [PMID: 42274921] A viral uveitis masquerade: PCR-confirmed Listeria monocytogenes necrotizing chorioretinitis complicated by secondary macular hole — *J Ophthalmic Inflamm Infect* (2026)
- [PMID: 42270295] Development of diagnostic criteria for Behçet's uveitis in a Chinese population — *Br J Ophthalmol* (2026)
- [PMID: 42259938] Stretchable high-fill-factor silicon-liquid metal platform for multilevel visual acquisition and depth sensing — *Nat Mater* (2026)